U.S., Oct. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07883213) titled 'A Study to Evaluate the Efficacy and Safety of AK139 in Patients With Prurigo Nodularis.' on Oct. 08.
Brief Summary: This is a multicenter, randomized, double-blind, placebo-controlled phase II clinical study to evaluate the efficacy and safety of AK139 in the treatment of subjects with prurigo nodularis. The total duration of the study (including screening period, treatment period and follow-up period) planned for each subject is approximately 24 weeks.
Study Start Date: Oct., 2026
Study Type: INTERVENTIONAL
Condition:
Prurigo Nodularis (PN)
Intervention:
BIOLOGICAL: AK139
Biological: AK139 low dose
OTHER: Placebo
Other: P...